SCHEMBL6718945

SCHEMBL6718945

COC(=O)c1ccc(NC(=O)N(S)C(C(=O)Nc2ccccc2)c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
GAA P10253 2/20 0.61
KMT2A Q03164 6/20 0.55
MEN1 O00255 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.52
POLB P06746 3/20 0.52
ROCK2 O75116 1/20 0.48
RAB9A P51151 4/20 0.48
MAPT P10636 4/20 0.48
LMNA P02545 2/20 0.48
PTPN1 P18031 1/20 0.47
THRB P10828 1/20 0.47
HTT P42858 2/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
NPC1 O15118 3/20 0.46
KDM4E B2RXH2 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715452 0.94 ALDH1A1 (0.57) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL6723214 0.92 ALDH1A1 (0.52) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL6714045 0.90 MAPT (0.61) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL6715747 0.80 MAPT (0.52) ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2
SCHEMBL6719554 0.77 NPY5R (0.50) ALDH1A1GAAKMT2AMEN1SMN1; SMN2
SCHEMBL6715845 0.75 GAA (0.51) ALDH1A1GAAKMT2AMEN1SMN1; SMN2
SCHEMBL31560108 0.75 ALDH1A1 (0.72) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL6719880 0.74 MAPT (0.58) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL6718944 0.74 MEN1 (0.68) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL6718048 0.74 KLK7 (0.46) ALDH1A1KMT2AMEN1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885L3MBTL1 3509/4885GAA 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.